Torrico F, et al. - The safety and efficacy of three oral E1224 (a water-soluble ravuconazole prodrug) regimens and benznidazole vs placebo were evaluated in adult chronic indeterminate Chagas disease. Researchers recognized E1224 as the first new chemical entity developed for Chagas disease in decades. A transient, suppressive effect on parasite clearance was observed with E1224, however, benznidazole demonstrated early and sustained efficacy until 12 months of follow-up. Results here supported increased diagnosis and access to benznidazole standard regimen, and provide a development roadmap for novel benznidazole regimens in monotherapy and in combinations with E1224, despite PCR limitations.